Immunocytokines: a novel class of potent armed antibodies
2012; Elsevier BV; Volume: 17; Issue: 11-12 Linguagem: Inglês
10.1016/j.drudis.2012.01.007
ISSN1878-5832
Autores Tópico(s)CAR-T cell therapy research
ResumoSeveral cytokines have been investigated in clinical trials, based on their potent therapeutic activity observed in animal models of cancer and other diseases. However, substantial toxicities are often reported at low doses, thus preventing escalation to therapeutically active regimens. The use of recombinant antibodies or antibody fragments as delivery vehicles promises to enhance greatly the therapeutic index of pro-inflammatory and anti-inflammatory cytokines. This review surveys preclinical and clinical data published in the field of antibody-cytokine fusions (immunocytokines). Molecular determinants (such as molecular format, valence, target antigen), which crucially contribute to immunocytokine performance in vivo, are discussed in the article, as well as recent trends for the combined use of this novel class of biopharmaceuticals with other therapeutic agents.
Referência(s)